Evidence map›Paper›PMID 40034956›Full record

ArticleCancer diagnosis & prognosis

Dose Reduction of

Akira Mochizuki, Hiroaki Matsumoto, Yosuke Maezawa, Shinichiro Okauchi, Gen Ohara, Shinya Sato, Kunihiko Miyazaki, Takahide Kodama, Hiroaki Satoh, Toshihiro Shiozawa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akira MochizukiDivision of Hospital Pharmacy, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Hiroaki MatsumotoDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Yosuke MaezawaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Gen OharaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Shinya SatoDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Takahide KodamaDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Yohei YatagaiDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: The Patients and Methods: Patient characteristics, treatment, overall survival, and progression-free survival of patients with Results: Of 165 patients, 67.3% received TKI dose reduction; patients who received TKI dose reduction had a smaller body surface area ( Conclusion: Reducing TKI dose is an option for patients with

Indexed as

dose reductionEGFR mutationEGFR-TKINon-small cell lung cancerosimertinib

Identifiers

PMID40034956
PMCPMC11871860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.